Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research Groups
Authors:
Open Access
- 1 November 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 2 (3) , pky050
Abstract
Research groups are increasingly utilizing value frameworks, but little is known of their reliability. To assess framework concordance and interrater reliability between two major value frameworks currently in use, we identified all previously published datasets containing both scores from the American Society of Clinical Oncology Value Framework (ASCO-VF) and grades from the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). The intraclass correlation coefficient (ICC) was used to assess interrater reliability. Four eligible studies contained drugs evaluated by both value frameworks, resulting in a dataset of 39 grades/scores for discrete drug indications. ICC was 0.82 (95% confidence interval = 0.70 to 0.90) for ASCO-VF and 0.88 (95% confidence interval = 0.80 to 0.93) for ESMO-MCBS. Absolute concordance was found to be 5% for ASCO-VF and 44% for ESMO-MCBS, increasing to 74% and 80% when deviations within 20 points and 1 grade were considered, respectively. Interrater reliability of ASCO-VF and ESMO-MCBS is, therefore, near perfect, while absolute concordance is poor. This has implications when considering framework outputs in drug funding or treatment decision making.Keywords
Funding Information
- Canadian Cancer Society Research Institute (2105-703549)
This publication has 14 references indexed in Scilit:
- Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworksThe Lancet Oncology, 2017
- Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic DrugsJournal of Oncology Practice, 2017
- Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology SettingJournal of Managed Care & Specialty Pharmacy, 2017
- Approvals in 2016: questioning the clinical benefit of anticancer therapiesNature Reviews Clinical Oncology, 2017
- Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015Annals of Oncology, 2017
- Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments ReceivedJournal of Clinical Oncology, 2016
- Five Years of Cancer Drug ApprovalsJAMA Oncology, 2015
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)Annals of Oncology, 2015
- Statistical notes for clinical researchers: Evaluation of measurement error 1: using intraclass correlation coefficientsRestorative Dentistry & Endodontics, 2013
- The Measurement of Observer Agreement for Categorical DataBiometrics, 1977